Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases.

Journal of medicinal chemistry·2026
Same author

Eligibility for hepatitis B virus (HBV) treatment and prevalence of drug resistance in a Ugandan population cohort.

The Journal of infection·2026
Same author

NF-κB-dependent GR cistrome redistribution recruits GR to inflammatory genes but correlates with lesser glucocorticoid-mediated repression.

iScience·2026
Same author

Micro-elimination of Hepatitis C virus (HCV) infection in the General Population Cohort in rural Uganda: Long-term follow-up to assess feasibility and outcomes of a screening and treatment intervention.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2026
Same author

Inflammatory cytokines promote interferon regulatory factor (IRF) transcriptional activity in human pulmonary epithelial cells through the induction of IRF1 by nuclear factor-κB.

PloS one·2025
Same author

Provincialising Global Oncology.

BMJ global health·2025
Same journal

Theranekron Prevents Endotoxin-Induced Acute Kidney Injury by Modulating Inflammatory and Mitochondrial Apoptotic Pathways.

European journal of pharmacology·2026
Same journal

Icariside Ⅱ alleviates heart failure based on Wnt/β-catenin-mitochondrial apoptotic pathway.

European journal of pharmacology·2026
Same journal

Tetrandrine improves obesity-induced adipose metabolic disorders through suppressing macrophage NF-κB activation.

European journal of pharmacology·2026
Same journal

HSP70: From Molecular Chaperone to Integrative Hub in Castration-Resistant Prostate Cancer Therapeutic Resistance.

European journal of pharmacology·2026
Same journal

Network pharmacology and in vivo validation reveal the protective mechanism of 6-gingerol against diabetic encephalopathy.

European journal of pharmacology·2026
Same journal

Corrigendum to "Piezo1 activation mediates stiffness-induced aortic medial calcification: Pharmacological evidence from agonist and antagonist studies" [Eur. J. Pharmacol. 1011 (2026) 178465].

European journal of pharmacology·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Anti-inflammatory glucocorticoids: changing concepts.

Robert Newton1

  • 1Department of Cell Biology and Anatomy, Airways Inflammation Research Group, Snyder Institute for Chronic Diseases, Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1.

European Journal of Pharmacology
|June 11, 2013
PubMed
Summary
This summary is machine-generated.

Glucocorticoids, effective anti-inflammatories, work partly through transactivation, boosting anti-inflammatory genes. Understanding this mechanism can improve therapies for inflammatory diseases.

Keywords:
Anti-inflammatoryCorticosteroidGlucocorticoidInflammationTransactivationTransrepression

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Related Experiment Videos

Last Updated: May 10, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Area of Science:

  • Molecular Biology
  • Immunology
  • Pharmacology

Background:

  • Glucocorticoids are potent anti-inflammatory drugs, yet their precise mechanisms remain unclear.
  • Key actions include transrepression and transactivation via the glucocorticoid receptor (NR3C1).

Purpose of the Study:

  • To elucidate the role of NR3C1 transactivation in glucocorticoid's anti-inflammatory effects.
  • To explore how transactivation contributes to therapeutic efficacy and resistance.

Main Methods:

  • Analysis of gene expression changes induced by glucocorticoids.
  • Investigation of NR3C1 interactions with transcription factors.
  • Examination of factors modulating NR3C1 transactivation.

Main Results:

  • Glucocorticoid transactivation upregulates genes like DUSP1, TSC22D3, NFKBIA, ZFP36, CDKN1C, and RGS2, which suppress inflammation.
  • Transactivation may be more potent than transrepression in reducing inflammatory gene expression.
  • NR3C1 transactivation is enhanced by β2-adrenoceptor agonists and reduced by viral infections.

Conclusions:

  • Glucocorticoid transactivation is a critical mechanism for potent anti-inflammatory effects.
  • Enhanced transactivation explains combination therapy benefits in asthma and COPD.
  • Reduced transactivation by inflammatory stimuli contributes to glucocorticoid resistance, offering therapeutic targets.